Literature DB >> 19885619

REIC/Dkk-3 stable transfection reduces the malignant phenotype of mouse prostate cancer RM9 cells.

Jie Chen1, Masami Watanabe, Peng Huang, Masakiyo Sakaguchi, Kazuhiko Ochiai, Yasutomo Nasu, Mamoru Ouchida, Nam-Ho Huh, Kenji Shimizu, Yuji Kashiwakura, Haruki Kaku, Hiromi Kumon.   

Abstract

The reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3, a member of the Dkk gene family, is a tumor suppressor in a broad range of cancers. REIC/Dkk-3 transfected stable clones of mouse prostate cancer RM9 cells (RM9-REIC) and the empty vector-transfected control clone cells (RM9-EV) were established. Clones were used to evaluate the anti-cancer effects and a proteomics analysis of REIC/Dkk-3 continuous expression was performed. The RM9-REIC cells show a feeble appearance and the cell membrane shows irregular buds known as blebs. In vitro cell proliferation was significantly suppressed in RM9-REIC clones in comparison to the control. The apoptosis assay was done under standard culture conditions and RM9-REIC showed a higher incidence of apoptosis. The RM9-EV and RM9-REIC cells were orthotopically implanted into a C57BL/6 mouse prostate. After 2 weeks, the tumor growth was significantly inhibited in RM9-REIC cells in comparison to the control. Two-dimensional gel electrophoresis was used to examine the modification of protein expression by the gene transfection. The analysis with mass spectrometry disclosed that expression of peroxiredoxin-1, GST-P1, transgelin-2, MRP-L12, ARD, GRP78 and Sorcin were increased and eEF1A-1 and cyclophilin-40 protein were decreased in RM9-REIC cells. Therefore, REIC/Dkk-3 stable transfectants show a reduction of malignancy in mouse prostate cancer RM9 cells in vitro and in vivo. The result of the proteomics analysis might provide important clues to clarify the anti-cancer molecular mechanism of REIC/Dkk-3 gene transfer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885619     DOI: 10.3892/ijmm_00000293

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Authors:  Thanh H Dellinger; Kestutis Planutis; Danielle D Jandial; Ramez N Eskander; Micaela E Martinez; Xiaolin Zi; Bradley J Monk; Randall F Holcombe
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

2.  Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro.

Authors:  Yu-Mei Gu; Yi-Hui Ma; Wu-Gan Zhao; Jie Chen
Journal:  World J Gastroenterol       Date:  2011-09-07       Impact factor: 5.742

3.  CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma.

Authors:  Stuart J Smith; Hanna Tilly; Jennifer H Ward; Donald C Macarthur; James Lowe; Beth Coyle; Richard G Grundy
Journal:  Acta Neuropathol       Date:  2012-02-07       Impact factor: 17.088

4.  Transgelin 2 participates in lovastatin-induced anti-angiogenic effects in endothelial cells through a phosphorylated myosin light chain-related mechanism.

Authors:  Yuan Xiao; Yuhua Li; Jing Han; Yan Pan; Lu Tie; Xuejun Li
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

5.  A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment.

Authors:  Kei Fujio; Masami Watanabe; Hideo Ueki; Shun-Ai Li; Rie Kinoshita; Kazuhiko Ochiai; Junichiro Futami; Toyohiko Watanabe; Yasutomo Nasu; Hiromi Kumon
Journal:  Oncol Rep       Date:  2015-01-29       Impact factor: 3.906

Review 6.  Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target.

Authors:  Theo Battista; Annarita Fiorillo; Valerio Chiarini; Ilaria Genovese; Andrea Ilari; Gianni Colotti
Journal:  Cancers (Basel)       Date:  2020-04-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.